Is C4 Therapeutics Inc (CCCC) overvalued? · rev $35.6M
C4 Therapeutics Inc (CCCC) is a biotechnology company listed on US.
This page asks whether C4 Therapeutics Inc (CCCC) looks expensive on cached numbers — not a short thesis.
Latest reported CCCC revenue for 2024-12-31 was $35.6M. Net income was -$105.3M. Revenue was up 71.4% from 2023-12-31 to 2024-12-31. CCCC currently screens at market cap $425.7M.
CCCC currently screens at market cap $425.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CCCC 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CCCC stock page for the full model, not this heading.
Not investment advice.